GSA Capital Partners’s Oramed Pharmaceuticals ORMP Stock Holding History

GSA Capital Partners’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-88,923	Closed	-$232K	–	1799
2023 Q3	$232K	Sell	88,923 -75,673	-46%	-$238K	0.02%	1217
2023 Q2	$589K	Buy	+164,596	New	+$528K	0.06%	643
2023 Q1	–	Sell	-46,039	Closed	-$554K	–	1814
2022 Q4	$554K	Buy	+46,039	New	+$358K	0.07%	540
2020 Q4	–	Sell	-19,659	Closed	-$51K	–	1501
2020 Q3	$51K	Buy	+19,659	New	+$68.5K	0.01%	1184

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

GSA Capital Partners's ORMP Position: Q4 2023 in Review

GSA Capital Partners sold out of Oramed Pharmaceuticals (ORMP) in Q4 2023, closing a stake of 88,923 shares — an estimated $232K sold.

GSA Capital Partners first reported a position in ORMP in Q3 2020 and held it in 4 quarters. The position peaked at $589K in Q2 2023. 56 funds tracked by Wall St. Rank hold ORMP as of Q4 2023.

GSA Capital Partners reported no remaining Oramed Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
GSA Capital Partners sold 88,923 Oramed Pharmaceuticals shares in Q4 2023, an estimated $232K.
GSA Capital Partners first reported a position in Oramed Pharmaceuticals in Q3 2020 and held it in 4 quarters.
GSA Capital Partners's Oramed Pharmaceuticals position peaked at $589K in Q2 2023.
56 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q4 2023.

Based on GSA Capital Partners's 13F filing for Q4 2023, filed 16 Feb 2024.